Self-Amplifying RNA Replicon for Sustained Cytokine Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy using DNA as a carrier faces challenges such as low delivery efficiency into cell nuclei, potential tumor formation, short expression time of mRNA, and the need for repeated administration, limiting its clinical application and patient compliance.
Innovation Solution
Development of an RNA replicon with specific mutations in the non-structural protein gene coding region, derived from alphaviruses, which can self-amplify and express target genes in the cytoplasm, reducing immunogenicity and allowing for repeated use without genome integration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DNA is used as a carrier for gene therapy, then the target gene can be delivered into cells, but the delivery efficiency into cell nucleus is low and tumor formation may occur
Solution Approach 1:
The patent extracts the harmful nuclear integration step from the gene delivery process by using mRNA instead of DNA. The mRNA is delivered directly to the cytoplasm where it can be translated without entering the nucleus, thereby eliminating the risk of genome integration and tumor formation while maintaining delivery efficiency through cytoplasmic targeting.
Solution Approach 2:
The patent introduces an intermediary delivery mechanism (such as lipid nanoparticles or other non-viral carriers) that facilitates mRNA delivery to the cytoplasm without requiring nuclear entry. This intermediary system enables efficient delivery while avoiding the harmful effects of DNA integration.
2Object-affected harmful factors
If mRNA is used for gene therapy, then safety is enhanced by avoiding genome integration, but the expression time is short and repeated administration is required
Solution Approach 1:
The patent employs a self-amplifying RNA system that utilizes the cell's own RNA-dependent RNA polymerase to replicate the therapeutic mRNA. This self-service mechanism allows the mRNA to amplify itself within the cell, extending the expression duration without requiring external intervention or repeated administration, while maintaining the safety advantages of mRNA.
Solution Approach 2:
The patent establishes continuity of useful action by designing an RNA replicon system that continuously produces the therapeutic protein through self-amplification. The replicated mRNA molecules continue to be translated until degradation occurs, providing sustained therapeutic effect without the need for repeated dosing.
3Reliability
If multiple repeated administration is performed to maintain therapeutic effect, then gene expression can be regulated, but patient compliance is limited and treatment cost increases
Solution Approach 1:
The self-amplifying RNA system performs the service of maintaining therapeutic effect autonomously within the cell. The RNA replicon continuously replicates itself and produces the therapeutic protein until degradation, eliminating the need for repeated patient administrations and improving compliance while maintaining reliable therapeutic effect.
4Adaptability or versatility
If structural protein genes are included in the replicon, then the virus can form, but immunogenicity increases and repeated injection is limited
Solution Approach 1:
The patent extracts the structural protein genes from the replicon, creating an incapacitated virus that cannot form complete virions. This extraction maintains the replicon's ability to replicate and express therapeutic genes while eliminating the immunogenicity associated with structural proteins, allowing for repeated injections.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNA replicon significantly enhances the expression of cytokines and chemokines like GM-CSF, IFN-γ, IL-2, and IL-15, providing a long-acting therapeutic effect with reduced dosage requirements, thus improving gene therapy efficacy and clinical potential.
Implementation Method 1
repRNA released into cytoplasm can serve as a template to duplicate and synthesize multiple transcripts via an RNA-dependent RNA polymerase
Data Source
AI summary
Disclosed in the present invention are an RNA replicon for improving gene expression, and a use thereof. The RNA replicon comprises: 5′ and 3′ untranslated regions; a non-structural protein gene coding region, a subgenomic promoter and a target gene coding region. In the present invention, a PCR site-directed mutagenesis technique is used to introduce the non-structural protein region mutant replicable RNA, which is transfected into mammalian eukaryotic cells by means of Lipofectamine 2000 or nanoparticles, so as to significantly enhance the expression of cytokines and chemokines including GM-CSF, IFN-γ, IL-2, IL-12, IL-15 mediated by downstream subgenomic promoters, and can be applied to treatment of tumors, infectious diseases, autoimmune diseases, hereditary diseases or cardiovascular diseases.